Find Calcifediol manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

JDMF

0

EU WC

0

KDMF

0

VMF

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

USP

0

JP

FINISHED DOSAGE FORMULATIONS

0

Canada

0

Australia

0

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

73RELATED EXCIPIENT COMPANIES

119EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Exclusivities

GLOBAL SALES INFORMATION

Annual Reports

NA

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Calcidiol, 25-hydroxyvitamin d3, 19356-17-3, 25-hydroxycholecalciferol, Calcifediol anhydrous, Hidroferol
Molecular Formula
C27H44O2
Molecular Weight
400.6  g/mol
InChI Key
JWUBBDSIWDLEOM-DTOXIADCSA-N
FDA UNII
T0WXW8F54E

Calcifediol
The major circulating metabolite of VITAMIN D3. It is produced in the LIVER and is the best indicator of the body's vitamin D stores. It is effective in the treatment of RICKETS and OSTEOMALACIA, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties.
Calcifediol anhydrous is a Vitamin D3 Analog.
1 2D Structure

Calcifediol

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
2.1.2 InChI
InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1
2.1.3 InChI Key
JWUBBDSIWDLEOM-DTOXIADCSA-N
2.1.4 Canonical SMILES
CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C
2.1.5 Isomeric SMILES
C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C
2.2 Other Identifiers
2.2.1 UNII
T0WXW8F54E
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 25 Hydroxycholecalciferol

2. 25 Hydroxycholecalciferol Monohydrate

3. 25 Hydroxyvitamin D 3

4. 25 Hydroxyvitamin D3

5. 25-hydroxycholecalciferol

6. 25-hydroxycholecalciferol Monohydrate

7. 25-hydroxyvitamin D 3

8. 25-hydroxyvitamin D3

9. Anhydrous, Calcifediol

10. Calcidiol

11. Calcifediol Anhydrous

12. Calcifediol, (3 Alpha,5z,7e)-isomer

13. Calcifediol, (3 Beta,5e,7e)-isomer

14. Calderol

15. Dedrogyl

16. Hidroferol

17. Monohydrate, 25-hydroxycholecalciferol

2.3.2 Depositor-Supplied Synonyms

1. Calcidiol

2. 25-hydroxyvitamin D3

3. 19356-17-3

4. 25-hydroxycholecalciferol

5. Calcifediol Anhydrous

6. Hidroferol

7. 25-hydroxyvitamin D

8. Calderol

9. Didrogyl

10. Calcifediolum

11. Rayaldee

12. Ro 8-8892

13. 5,6-cis-25-hydroxyvitamin D3

14. Calcifediol [inn]

15. Cholecalciferol, 25-hydroxy-

16. Chebi:17933

17. (3s,5z,7e)-9,10-secocholesta-5,7,10-triene-3,25-diol

18. T0wxw8f54e

19. 3-{2-[1-(5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexanol

20. Ncgc00161326-04

21. Calcifidiol

22. Delakmin

23. 25-hydroxy Vitamin D3

24. (3beta,5z,7e)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol

25. (5z,7e)-(3s)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol

26. U-32070e

27. U 32070 E

28. 25-hydroxyvitamin D3 / 25-hydroxycholecalciferol / Calcidiol

29. 25-hydroxycholescalciferol

30. Calcifediolum [inn-latin]

31. Rovimix Hy-d

32. (1s,3z)-3-{2-[(1r,3as,4e,7ar)-1-[(2r)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1h-inden-4-ylidene]ethylidene}-4-methylidenecyclohexan-1-ol

33. (3b,5z,7e)- 9,10-secocholesta-5,7,10(19)-triene-3,25-diol

34. Vitamin D, 25-hydroxy-

35. Hy-d

36. (1s,3z)-3-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol

37. 36149-00-5

38. 25-(oh)vitamin D3

39. 5,6-trans-25-hydroxycholescalciferol

40. Unii-t0wxw8f54e

41. Ryaldee

42. Bml2-e02

43. (5z,7e)-(3s)-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol

44. 25(oh)d3

45. Einecs 242-990-9

46. Mfcd00867077

47. U 32070e

48. Calcifediol [mi]

49. (5z,7e)-9,10-seco-5,7,10(19)-cholestatrien-3beta,25-diol

50. 5,6-trans-9,10-seco-5,7,10(19)-cholestatrien-3beta,25-diol

51. Spectrum5_001931

52. Dsstox_cid_2721

53. 25-hydroxy-cholecalciferol

54. Calcifediol,anhydrous

55. Schembl3296

56. Chembl1040

57. Dsstox_rid_76699

58. Dsstox_gsid_22721

59. Bspbio_001411

60. Calcifediol, Anhydrous

61. (3s,5z,7e)-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol

62. Gtpl6921

63. Dtxsid0022721

64. Chebi:94743

65. Amy2863

66. Bcpp000306

67. Dm100

68. Hms1361g13

69. Hms1791g13

70. Hms1989g13

71. Hms2089l21

72. Hms3402g13

73. 64719-49-9

74. Act06833

75. Zinc4474414

76. Tox21_111987

77. (3s,5z,7e)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol

78. 9,10-secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5z,7e)-

79. Bdbm50521013

80. Calcifediol,anhydrous [vandf]

81. Lmst03020246

82. S1469

83. Akos015965097

84. Bcp9000472

85. Ccg-268657

86. Cs-0800

87. Db00146

88. Idi1_033881

89. Ncgc00161326-01

90. Ac-31367

91. Hy-32351

92. Cas-19356-17-3

93. 25-hydroxycholecalciferol, >=98% (hplc)

94. C01561

95. Ab01275461-01

96. Ab01275461_02

97. 356c173

98. A923587

99. Q139307

100. Sr-05000001468

101. Sr-05000001468-1

102. W-201718

103. 25-hydroxyvitamin D3 Monohydrate, >=99.0% (hplc)

104. 9,10-secocholesta-5,7,10(19)-triene-3b,25-diol

105. Brd-k77175907-001-01-5

106. B91135ec-8937-4d8b-a533-ccd82f33c1b0

107. Calcifediol, European Pharmacopoeia (ep) Reference Standard

108. (5e,7e)-9,10-secocholesta-5,7,10(19)-triene-3beta,25-diol

109. 25-hydroxyvitamin D3 Solution, 100 Mug/ml In Ethanol, 98% (cp)

110. 25-hydroxyvitamin D3 Solution, 5 Mug/ml In Ethanol, 98% (cp)

111. 25-hydroxyvitamin D3 Solution, 50 Mug/ml In Ethanol, 98% (cp)

112. Calcifediol, United States Pharmacopeia (usp) Reference Standard

113. (3s,5z,14beta,17alpha)-9,10-secocholesta-5,7,10-triene-3,25-diol

114. (5z,7e)-9,10-secocholesta-5,7,10(19)-triene-3b,25-diol Monohydrate

115. 9,10-secocholesta-5,7,10(19)-triene-1,25-diol, (3.beta,.5z,7e)-

116. (?r,1r,3as,4e,7ar)-4-[(2z)-2-[(5s)-5-hydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-?,?,?,7a-tetramethyl-1h-indene-1-pentanol

117. (1s,3z)-3-[(2e)-2-[(1r,3as,7ar)-1-[(1r)-5-hydroxy-1,5-dimethyl-hexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylene-cyclohexanol

118. (s,z)-3-((e)-2-((1r,3as,7ar)-1-((r)-6-hydroxy-6-methylheptan-2-yl)-7a-methylhexahydro-1h-inden-4(2h)-ylidene)ethylidene)-4-methylenecyclohexanol

119. 1h-indene-1-pentanol, Octahydro-4-[(2z)-2-[(5s)-5-hydroxy-2-methylenecyclohexylidene]ethylidene]-.alpha.,.alpha.,.epsilon.,7a-tetramethyl-, (.epsilon.r,1r,3as,4e,7ar)-

120. 25-hydroxyvitamin D3 Solution, 100 Mug/ml In Ethanol, Ampule Of 1 Ml, Certified Reference Material

121. 25-hydroxyvitamin D3 Solution, 5 Mug/ml In Ethanol, Ampule Of 1 Ml, Certified Reference Material

2.4 Create Date
2004-09-16
3 Chemical and Physical Properties
Molecular Weight 400.6 g/mol
Molecular Formula C27H44O2
XLogP36.2
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count2
Rotatable Bond Count6
Exact Mass400.334130642 g/mol
Monoisotopic Mass400.334130642 g/mol
Topological Polar Surface Area40.5 Ų
Heavy Atom Count29
Formal Charge0
Complexity655
Isotope Atom Count0
Defined Atom Stereocenter Count5
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count2
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Used to treat vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.


Treatment of secondary hyperparathyroidism (SHPT)


5 Pharmacology and Biochemistry
5.1 Pharmacology

Calcidiol is the precursor of vitamin D3. Vitamin D3 is a steroid hormone that has long been known for its important role in regulating body levels of calcium and phosphorus, in mineralization of bone, and for the assimilation of vitamin A. The classical manifestations of vitamin D deficiency is rickets, which is seen in children and results in bony deformaties including bowed long bones. Deficiency in adults leads to the disease osteomalacia. Both rickets and osteomalacia reflect impaired mineralization of newly synthesized bone matrix, and usually result from a combination of inadequate exposure to sunlight and decreased dietary intake of vitamin D. Common causes of vitamin D deficiency include genetic defects in the vitamin D receptor, severe liver or kidney disease, and insufficient exposure to sunlight. Vitamin D plays an important role in maintaining calcium balance and in the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of calcium, increases intestinal absorption of calcium and phosphorus, and increases calcium and phosphorus mobilization from bone to plasma.


5.2 MeSH Pharmacological Classification

Bone Density Conservation Agents

Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)


Vitamins

Organic substances that are required in small amounts for maintenance and growth, but which cannot be manufactured by the human body. (See all compounds classified as Vitamins.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
CALCIFEDIOL ANHYDROUS
5.3.2 FDA UNII
T0WXW8F54E
5.3.3 Pharmacological Classes
Vitamin D3 Analog [EPC]; Cholecalciferol [CS]
5.4 ATC Code

A - Alimentary tract and metabolism

A11 - Vitamins

A11C - Vitamin a and d, incl. combinations of the two

A11CC - Vitamin d and analogues

A11CC06 - Calcifediol


H - Systemic hormonal preparations, excl. sex hormones and insulins

H05 - Calcium homeostasis

H05B - Anti-parathyroid agents

H05BX - Other anti-parathyroid agents

H05BX05 - Calcifediol


5.5 Absorption, Distribution and Excretion

Absorption

Readily absorbed.


5.6 Metabolism/Metabolites

Calcidiol undergoes hydroxylation in the mitochondria of kidney tissue, and this reaction is activated by the renal 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to produce calcitriol (1,25- dihydroxycholecalciferol), the active form of vitamin D3.


5.7 Biological Half-Life

288 hours


5.8 Mechanism of Action

Calcidiol is transformed in the kidney by 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to calcitriol, the active form of vitamin D3. Calcitriol binds to intracellular receptors that then function as transcription factors to modulate gene expression. Like the receptors for other steroid hormones and thyroid hormones, the vitamin D receptor has hormone-binding and DNA-binding domains. The vitamin D receptor forms a complex with another intracellular receptor, the retinoid-X receptor, and that heterodimer is what binds to DNA. In most cases studied, the effect is to activate transcription, but situations are also known in which vitamin D suppresses transcription. Calcitriol increases the serum calcium concentrations by: increasing GI absorption of phosphorus and calcium, increasing osteoclastic resorption, and increasing distal renal tubular reabsorption of calcium. Calcitriol appears to promote intestinal absorption of calcium through binding to the vitamin D receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein.


Drugs in Development

read-more
read-more

Details:

As part of the expanded collaboration, Calcifediol will target the Vitamin D receptor to address secondary hyperparathyroidism.


Lead Product(s): Calcifediol,Inapplicable

Therapeutic Area: Endocrinology Brand Name: Rayaldee

Study Phase: Approved FDFProduct Type: Vitamins/Minerals/Inorganic Salts

Sponsor: Nicoya Therapeutics (Shanghai) Co., Ltd.

Deal Size: $115.0 million Upfront Cash: Undisclosed

Deal Type: Expanded Collaboration April 30, 2026

blank

01

EirGen Pharma

Ireland
arrow
PEGS Boston Summit
Not Confirmed

EirGen Pharma

Ireland
arrow
PEGS Boston Summit
Not Confirmed

Lead Product(s) : Calcifediol,Inapplicable

Therapeutic Area : Endocrinology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Nicoya Therapeutics (Shanghai) Co., Ltd.

Deal Size : $115.0 million

Deal Type : Expanded Collaboration

Details : As part of the expanded collaboration, Calcifediol will target the Vitamin D receptor to address secondary hyperparathyroidism.

Product Name : Rayaldee

Product Type : Vitamins/Minerals/Inorganic Salts

Upfront Cash : Undisclosed

April 30, 2026

blank

Details:

CTAP101 (Calcifediol) is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Renal Insufficiency, Chronic.


Lead Product(s): Calcifediol,Inapplicable

Therapeutic Area: Nephrology Brand Name: CTAP101

Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 27, 2026

blank

02

OPKO Health

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

OPKO Health

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Details : CTAP101 (Calcifediol) is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Renal Insufficiency, Chronic.

Product Name : CTAP101

Product Type : Vitamins/Minerals/Inorganic Salts

Upfront Cash : Inapplicable

March 27, 2026

blank

Details:

RAYALDEE extended-release capsules are indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.


Lead Product(s): Calcifediol,Inapplicable

Therapeutic Area: Endocrinology Brand Name: Rayaldee

Study Phase: Approved FDFProduct Type: Vitamins/Minerals/Inorganic Salts

Sponsor: VFMCRP

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 03, 2022

blank

03

OPKO Health

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

OPKO Health

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Details : RAYALDEE extended-release capsules are indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

Product Name : Rayaldee

Product Type : Vitamins/Minerals/Inorganic Salts

Upfront Cash : Inapplicable

February 03, 2022

blank

Details:

Rayaldee is an extended-release oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3. The product is the first and only medicine approved by the US FDA for raising serum total 25D and lowering blood levels of intact iPTH.


Lead Product(s): Calcifediol,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Rayaldee

Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 30, 2021

blank

04

OPKO Health

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

OPKO Health

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Details : Rayaldee is an extended-release oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3. The product is the first and only medicine approved by the US FDA for raising serum total 25D and lowering blood levels of intact ...

Product Name : Rayaldee

Product Type : Vitamins/Minerals/Inorganic Salts

Upfront Cash : Inapplicable

August 30, 2021

blank

Details:

RAYALDEE is an extended-release oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3. The REsCue trial randomized symptomatic COVID-19 outpatients in a 1:1 ratio to 4 weeks of treatment with RAYALDEE or placebo and a 2-week follow-up.


Lead Product(s): Calcifediol,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Rayaldee

Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 30, 2021

blank

05

OPKO Health

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

OPKO Health

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Details : RAYALDEE is an extended-release oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3. The REsCue trial randomized symptomatic COVID-19 outpatients in a 1:1 ratio to 4 weeks of treatment with RAYALDEE or placebo and a...

Product Name : Rayaldee

Product Type : Vitamins/Minerals/Inorganic Salts

Upfront Cash : Inapplicable

August 30, 2021

blank

Details:

OPKO Health announced a transfer of the licensed rights to RAYALDEE in Japan from Japan Tobacco to Vifor Fresenius Medical Care Renal Pharma (VFMCRP). EirGen and VFMCRP have agreed to transfer the rights to RAYALDEE® in Japan to VFMCRP.


Lead Product(s): Calcifediol,Inapplicable

Therapeutic Area: Endocrinology Brand Name: Rayaldee

Study Phase: Approved FDFProduct Type: Vitamins/Minerals/Inorganic Salts

Sponsor: CSL Vifor

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Termination May 24, 2021

blank

06

OPKO Health

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

OPKO Health

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Details : OPKO Health announced a transfer of the licensed rights to RAYALDEE in Japan from Japan Tobacco to Vifor Fresenius Medical Care Renal Pharma (VFMCRP). EirGen and VFMCRP have agreed to transfer the rights to RAYALDEE® in Japan to VFMCRP.

Product Name : Rayaldee

Product Type : Vitamins/Minerals/Inorganic Salts

Upfront Cash : Undisclosed

May 24, 2021

blank

Details:

Calcifediol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Vitamin D Deficiency.


Lead Product(s): Calcifediol,Inapplicable

Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed

Study Phase: Phase II/ Phase IIIProduct Type: Vitamins/Minerals/Inorganic Salts

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 03, 2021

blank

07

Faes Farma

Spain
arrow
PEGS Boston Summit
Not Confirmed

Faes Farma

Spain
arrow
PEGS Boston Summit
Not Confirmed

Details : Calcifediol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Vitamin D Deficiency.

Product Name : Undisclosed

Product Type : Vitamins/Minerals/Inorganic Salts

Upfront Cash : Inapplicable

February 03, 2021

blank

Details:

Rayaldee (Calcifediol) is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.


Lead Product(s): Calcifediol,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Rayaldee

Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 16, 2020

blank

08

OPKO Health

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

OPKO Health

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Details : Rayaldee (Calcifediol) is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

Product Name : Rayaldee

Product Type : Vitamins/Minerals/Inorganic Salts

Upfront Cash : Inapplicable

September 16, 2020

blank

Details:

The randomized, double-blind placebo-controlled study will evaluate the safety and efficacy of RAYALDEE (calcifediol) extended-release capsules to treat symptomatic patients infected with SARS-CoV-2 (REsCue).


Lead Product(s): Calcifediol,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Rayaldee

Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 15, 2020

blank

09

OPKO Health

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

OPKO Health

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Details : The randomized, double-blind placebo-controlled study will evaluate the safety and efficacy of RAYALDEE (calcifediol) extended-release capsules to treat symptomatic patients infected with SARS-CoV-2 (REsCue).

Product Name : Rayaldee

Product Type : Vitamins/Minerals/Inorganic Salts

Upfront Cash : Inapplicable

September 15, 2020

blank

Details:

The REsCue trial will have 4 weeks of treatment with RAYALDEE or placebo and 2 weeks of follow-up. The objective is to raise and maintain serum total 25-hydroxyvitamin D (25D) within the range of 50-100 ng/mL in order to mitigate COVID-19 severity.


Lead Product(s): Calcifediol,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Rayaldee

Study Phase: Phase IIProduct Type: Vitamins/Minerals/Inorganic Salts

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 01, 2020

blank

10

OPKO Health

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

OPKO Health

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Details : The REsCue trial will have 4 weeks of treatment with RAYALDEE or placebo and 2 weeks of follow-up. The objective is to raise and maintain serum total 25-hydroxyvitamin D (25D) within the range of 50-100 ng/mL in order to mitigate COVID-19 severity.

Product Name : Rayaldee

Product Type : Vitamins/Minerals/Inorganic Salts

Upfront Cash : Inapplicable

June 01, 2020

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Calcifediol

Brand Name : Filibon

Dosage Form : CAP

Dosage Strength : 400u

Packaging : 30X1u

Approval Date :

Application Number :

Regulatory Info : Generic

Registration Country : South Africa

Aspen API Comapny Banner

02

Biomed

Australia
PEGS Boston Summit
Not Confirmed
arrow

Biomed

Australia
arrow
PEGS Boston Summit
Not Confirmed

Calcifediol

Brand Name : Vitafediol

Dosage Form : Soft Capsule

Dosage Strength : 0.266mg

Packaging :

Approval Date : 17/07/2024

Application Number : 69012

Regulatory Info : Allowed

Registration Country : Switzerland

blank

03

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Calcifediol

Brand Name : DIDROGYL

Dosage Form : Oral Drops Solution

Dosage Strength : 1.5 mg/10 ml

Packaging : 10 ML 0.15 MG/ML - ORAL USE

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank

04

CSL Vifor

Switzerland
PEGS Boston Summit
Not Confirmed
arrow

CSL Vifor

Switzerland
arrow
PEGS Boston Summit
Not Confirmed

Calcifediol

Brand Name : Rayaldee ?g

Dosage Form : Extended Release Capsule

Dosage Strength : 30mcg

Packaging :

Approval Date : 22/12/2020

Application Number : 67614

Regulatory Info : Allowed

Registration Country : Switzerland

blank

05

EirGen Pharma

Ireland
PEGS Boston Summit
Not Confirmed
arrow

EirGen Pharma

Ireland
arrow
PEGS Boston Summit
Not Confirmed

CALCIFEDIOL

Brand Name : RAYALDEE

Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL

Dosage Strength : 0.03MG

Packaging :

Approval Date : 2016-06-17

Application Number : 208010

Regulatory Info : RX

Registration Country : USA

blank

06

Faes Farma

Spain
PEGS Boston Summit
Not Confirmed
arrow

Faes Farma

Spain
arrow
PEGS Boston Summit
Not Confirmed

Calcifediol

Brand Name : Hidroferol

Dosage Form : Soft Capsule

Dosage Strength :

Packaging :

Approval Date : 30-11-2023

Application Number :

Regulatory Info :

Registration Country : Moldova

blank

07

IBN Savio

Italy
PEGS Boston Summit
Not Confirmed
arrow

IBN Savio

Italy
arrow
PEGS Boston Summit
Not Confirmed

Calcifediol

Brand Name : VIDENKA

Dosage Form : Oral Drops Solution

Dosage Strength : 0.15 mg/ml

Packaging : 10 ML 0.15 MG/ML - ORAL USE

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank

08

Merck & Co

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

Merck & Co

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

CALCIFEDIOL

Brand Name : CALDEROL

Dosage Form : CAPSULE;ORAL

Dosage Strength : 0.02MG

Packaging :

Approval Date : 1982-01-01

Application Number : 18312

Regulatory Info : DISCN

Registration Country : USA

blank

09

Merck & Co

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

Merck & Co

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

CALCIFEDIOL

Brand Name : CALDEROL

Dosage Form : CAPSULE;ORAL

Dosage Strength : 0.05MG

Packaging :

Approval Date : 1982-01-01

Application Number : 18312

Regulatory Info : DISCN

Registration Country : USA

blank

10

Country
PEGS Boston Summit
Not Confirmed
arrow

Country
arrow
PEGS Boston Summit
Not Confirmed

Calcifediol

Brand Name : Didrogyl

Dosage Form : Calcifediolo 1,5Mg/10Ml Oral Use

Dosage Strength : os gtt soluz 1.5 mg 10 ml

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

EIRGEN

Ireland
PEGS Boston Summit
Not Confirmed
arrow

EIRGEN

Ireland
arrow
PEGS Boston Summit
Not Confirmed

CALCIFEDIOL

Brand Name : RAYALDEE

Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL

Dosage Strength : 0.03MG

Approval Date : 2016-06-17

Application Number : 208010

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

02

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

CALCIFEDIOL

Brand Name : CALDEROL

Dosage Form : CAPSULE;ORAL

Dosage Strength : 0.02MG

Approval Date : 1982-01-01

Application Number : 18312

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

03

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

CALCIFEDIOL

Brand Name : CALDEROL

Dosage Form : CAPSULE;ORAL

Dosage Strength : 0.05MG

Approval Date : 1982-01-01

Application Number : 18312

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Coating Systems & Additives

read-more
read-more
click full view

Film Formers & Plasticizers

read-more
read-more

Controlled & Modified Release

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Taste Masking

read-more
read-more

Empty Capsules

read-more
read-more

Vegetarian Capsules

read-more
read-more

Solubilizers

read-more
read-more

Topical

read-more
read-more

API Stability Enhancers

read-more
read-more

Emulsifying Agents

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Parenteral

read-more
read-more

Granulation

read-more
read-more

Coloring Agents

read-more
read-more

Direct Compression

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Rheology Modifiers

read-more
read-more

Co-Processed Excipients

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Looking for 19356-17-3 / Calcifediol API manufacturers, exporters & distributors?

Calcifediol manufacturers, exporters & distributors 1

87

PharmaCompass offers a list of Calcifediol API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Calcifediol manufacturer or Calcifediol supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Calcifediol manufacturer or Calcifediol supplier.

API | Excipient name

Calcifediol

Synonyms

Calcidiol, 25-hydroxyvitamin d3, 19356-17-3, 25-hydroxycholecalciferol, Calcifediol anhydrous, Hidroferol

Cas Number

19356-17-3

Unique Ingredient Identifier (UNII)

T0WXW8F54E

About Calcifediol

The major circulating metabolite of VITAMIN D3. It is produced in the LIVER and is the best indicator of the body's vitamin D stores. It is effective in the treatment of RICKETS and OSTEOMALACIA, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties.

Didrogyl Manufacturers

A Didrogyl manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Didrogyl, including repackagers and relabelers. The FDA regulates Didrogyl manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Didrogyl API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Didrogyl manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Didrogyl Suppliers

A Didrogyl supplier is an individual or a company that provides Didrogyl active pharmaceutical ingredient (API) or Didrogyl finished formulations upon request. The Didrogyl suppliers may include Didrogyl API manufacturers, exporters, distributors and traders.

click here to find a list of Didrogyl suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Didrogyl USDMF

A Didrogyl DMF (Drug Master File) is a document detailing the whole manufacturing process of Didrogyl active pharmaceutical ingredient (API) in detail. Different forms of Didrogyl DMFs exist exist since differing nations have different regulations, such as Didrogyl USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Didrogyl DMF submitted to regulatory agencies in the US is known as a USDMF. Didrogyl USDMF includes data on Didrogyl's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Didrogyl USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Didrogyl suppliers with USDMF on PharmaCompass.

Didrogyl CEP

A Didrogyl CEP of the European Pharmacopoeia monograph is often referred to as a Didrogyl Certificate of Suitability (COS). The purpose of a Didrogyl CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Didrogyl EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Didrogyl to their clients by showing that a Didrogyl CEP has been issued for it. The manufacturer submits a Didrogyl CEP (COS) as part of the market authorization procedure, and it takes on the role of a Didrogyl CEP holder for the record. Additionally, the data presented in the Didrogyl CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Didrogyl DMF.

A Didrogyl CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Didrogyl CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of Didrogyl suppliers with CEP (COS) on PharmaCompass.

Didrogyl NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Didrogyl as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Didrogyl API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Didrogyl as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Didrogyl and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Didrogyl NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Didrogyl suppliers with NDC on PharmaCompass.

Didrogyl GMP

Didrogyl Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Didrogyl GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Didrogyl GMP manufacturer or Didrogyl GMP API supplier for your needs.

Didrogyl CoA

A Didrogyl CoA (Certificate of Analysis) is a formal document that attests to Didrogyl's compliance with Didrogyl specifications and serves as a tool for batch-level quality control.

Didrogyl CoA mostly includes findings from lab analyses of a specific batch. For each Didrogyl CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Didrogyl may be tested according to a variety of international standards, such as European Pharmacopoeia (Didrogyl EP), Didrogyl JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Didrogyl USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty